TScan Therapeutics, Inc.
TCRX
$1.27
-$0.11-7.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.17M | 665.00K | 1.05M | 536.00K | 566.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.17M | 665.00K | 1.05M | 536.00K | 566.00K |
| Cost of Revenue | 29.79M | -73.15M | 26.26M | 26.88M | 24.86M |
| Gross Profit | -27.62M | 73.82M | -25.21M | -26.34M | -24.29M |
| SG&A Expenses | 8.63M | 8.02M | 7.41M | 7.77M | 7.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.42M | 37.38M | 33.67M | 34.65M | 31.94M |
| Operating Income | -36.25M | -36.71M | -32.62M | -34.11M | -31.37M |
| Income Before Tax | -34.13M | -35.81M | -29.89M | -31.66M | -30.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.13M | -35.81M | -29.89M | -31.66M | -30.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.13M | -35.81M | -29.89M | -31.66M | -30.14M |
| EBIT | -36.25M | -36.71M | -32.62M | -34.11M | -31.37M |
| EBITDA | -35.57M | -36.00M | -31.60M | -33.00M | -30.12M |
| EPS Basic | -0.26 | -0.63 | -0.56 | -0.60 | -0.63 |
| Normalized Basic EPS | -0.16 | -0.38 | -0.35 | -0.37 | -0.39 |
| EPS Diluted | -0.26 | -0.63 | -0.56 | -0.60 | -0.63 |
| Normalized Diluted EPS | -0.16 | -0.38 | -0.35 | -0.37 | -0.39 |
| Average Basic Shares Outstanding | 129.68M | 56.59M | 53.35M | 52.93M | 47.90M |
| Average Diluted Shares Outstanding | 129.68M | 56.59M | 53.35M | 52.93M | 47.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |